Table 3. Univariate analysis.
| p value | HR | 95% CI | |
|---|---|---|---|
| Age (years) (<75/≥75) | 0.062 | 2.13 | 0.96–4.69 |
| Gender (male/female) | 0.003 | 0.25 | 0.1–0.63 |
| Brinkman index (<600/≥600) | 0.088 | 2.03 | 0.9–4.57 |
| ECOG-PS (0/1-2) | 0.061 | 3.17 | 0.95–10.6 |
| Hugh-Jones classification (1/2–3) | 0.066 | 3.16 | 0.93–10.78 |
| BMI, kg/m2 (≤18.5/>18.5) | 0.217 | 1.97 | 0.67–5.76 |
| Surgical procedure | |||
| (Sublobar resection/lobectomy or greater) | 0.608 | 1.27 | 0.51–3.19 |
| Lymphatic permeation (absent/present) | 0.519 | 1.42 | 0.49–4.15 |
| Vascular invasion (absent/present) | 0.096 | 2.18 | 0.87–5.46 |
| Stage IA (1-2/3) | 0.713 | 0.83 | 0.31–2.22 |
| Histological subtype (lepidic/non-lepidic) | 0.454 | 1.35 | 0.62–2.97 |
| CEA, ng/mL, (≤5/>5) | 0.007 | 3.55 | 1.41–8.92 |
| GPS (0/1-2) | 0.023 | 3.47 | 1.19–10.12 |
| RDW (<13.3/≥13.3) | 0.017 | 2.8 | 1.2–6.5 |
| NLR (<3.43/≥3.43) | 0.002 | 3.87 | 1.66–9.03 |
| PLR (<120/≥120) | 0.063 | 1.01 | 1.0–1.01 |
| ALI (≥22.2/<22.2) | <0.001 | 6.81 | 2.97–15.59 |
| %VC (<80/≥80) | 0.075 | 2.66 | 0.91–7.8 |
| %FEV1 (<80/≥80) | 0.635 | 0.75 | 0.22–2.5 |
| %DLCO (<80/≥80) | 0.213 | 2.16 | 0.64–7.28 |
ECOG: eastern cooperative oncology group; PS: performance status; CEA: carcinoembryonic antigen; GPS: glasgow prognostic score; RDW: red cell distribution width; PLR: platelet-to-lymphocyte ratio; NLR: neutrophilto-lymphocyte ratio; ALI: advanced lung cancer inflammation index; VC: vital capacity; FEV: forced expiratory volume; DLCO: diffusing capacity of lung carbon monoxide; BMI: body mass index; HR: hazard ratio; CI: confidence interval